NurExone Biologic Inc. (TSXV:NRX)
Canada · Delayed Price · Currency is CAD | Market Cap | 48.20M -18.4% |
| Revenue (ttm) | n/a |
| Net Income | -8.96M |
| EPS | -0.10 |
| Shares Out | 96.40M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,000 |
| Open | 0.5000 |
| Previous Close | 0.5000 |
| Day's Range | 0.4900 - 0.5000 |
| 52-Week Range | 0.4350 - 0.7600 |
| Beta | 0.34 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Dec 1, 2026 |
About NurExone Biologic
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It offers ExoPTEN, for treatment of acute spinal cord injuries. The company was founded in 2020 and is based in Toronto, Canada. [Read more]
News
NurExone Demonstrates Consistent Anti-Inflammatory Activity Across Three Separate Batches of Exosomes
New results strengthen the foundation for commercial naïve exosome supply and continued development of ExoPTEN New results strengthen the foundation for commercial naïve exosome supply and continued d...
NurExone Demonstrates Scalable Exosome Production, Supporting Its Modular Manufacturing Strategy and Commercial Growth
TORONTO and HAIFA, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-...
NurExone Expands U.S. Engagement Across Four Major Boston Life Sciences Events and Provides Corporate Update
CEO Dr. Lior Shaltiel and R&D Director Dr. Tali Kizhner to engage with industry, investors and scientific leaders during a concentrated week in Boston CEO Dr. Lior Shaltiel and R&D Director Dr. Tali K...
NurExone Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update
Shareholders grant the Board discretionary authority to implement a share consolidation of up to 30:1 Shareholders grant the Board discretionary authority to implement a share consolidation of up to 3...
NurExone and NanoPass Technologies Ltd. to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin Applications
Collaboration to evaluate MicronJet™ with NurExone exosomes across ophthalmic and aesthetic applications in multi-billion-dollar markets Collaboration to evaluate MicronJet™ with NurExone exosomes acr...
NurExone Biologic Inc. Announces Second Quarter 2026 Financial Results
TORONTO and HAIFA, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-base...
NurExone Biologic Inc. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
TORONTO and HAIFA, Israel, Aug. 28, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-base...
NurExone Announces Annual General and Special Meeting to Consider Share Consolidation in Support of U.S. Capital Markets Strategy
Proposed share consolidation of up to 30:1 intended to support potential U.S. exchange listing and broaden investor appeal
NurExone Announces Closing of C$1,066,078 Private Placement
TORONTO, and HAIFA, Israel, Aug. 21, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome...
NurExone Reports New Preclinical Tissue-Analysis Data Supporting Potential Neuroprotective Effect of ExoPTEN in Acute Spinal Cord Injury Animal Model
Tissue analysis showed significantly higher numbers of myelin-positive cells in ExoPTEN-treated animals compared with controls, providing additional preclinical biological support for previously repor...
NurExone Announces Binding MOU with Made Scientific for U.S. GMP Manufacturing and Commercial Supply Partnership
The Signed MOU Targets Initial GMP Exosome Batches in H1 2027 to Support NurExone's Clinical Pipeline and Planned Commercial Production The Signed MOU Targets Initial GMP Exosome Batches in H1 2027 to...
NurExone Launches Bioprocess Optimization Initiative to Support Commercial and Clinical Readiness
TORONTO and HAIFA, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF, FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based ...
Corporate Updates – NurExone appoints Mr. David Stolick to the Board of Directors
TORONTO, Ontario and HAIFA, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing...
NurExone Announces Closing of Non-Brokered Private Placement
TORONTO, Ontario and HAIFA, Israel, June 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing...
Exo-Top, NurExone's wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico
TORONTO, Ontario and HAIFA, Israel, June 25, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing...
NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update
TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing...
Water Tower Research Publishes Initiation of Coverage Report on NurExone Biologic, Inc., “A Novel Exosome Therapy Platform at the Frontier of CNS Regeneration”
May 21, 2026, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on NurExone Biologic, Inc. (TSXV: NRX/OTCQB: NRBXF) titled, “A Novel...
NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology
Expands intellectual property protection in a strategically important market for the Company's lead exosome-based therapy targeting nerve repair and functional recovery Expands intellectual property p...
NurExone Advances to Stage 2 of EU-Backed EIT Health Catapult Programme 2026
TORONTO, Ontario and HAIFA, Israel, May 14, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing ...
Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production
Sheba medical center researcher to present NurExone's exosome optic nerve regeneration work at ISCEV@Denver Sheba medical center researcher to present NurExone's exosome optic nerve regeneration work ...
NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
TORONTO, Ontario and HAIFA, Israel, April 16, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company developin...
NurExone to Participate in Water Tower Research Insights Conference on April 14, 2026
Toronto, Ontario and Haifa, Israel--(Newsfile Corp. - April 10, 2026) - NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biotechnology company developing e...
NurExone Biologic's U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization
TORONTO, Ontario and HAIFA, Israel and POMPANO BEACH, Florida, April 07, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) and BioXtek...
NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy
TORONTO and HAIFA, Israel, April 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-bas...
NurExone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement
Exo-Top Inc. positioned as a strategic U.S. subsidiary supporting manufacturing, clinical advancement and long-term value creation Exo-Top Inc. positioned as a strategic U.S. subsidiary supporting man...